Cadrenal pushes tecarfarin into ESKD trials as cash burn, rising G&A heighten financing risk

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) - Quick internal read

Management is advancing tecarfarin into late-stage clinical activity (announced trial plans for ESKD patients on August 5, 2025) while burning cash to support operations and public-company overhead. The company used its ATM program and past warrant exercises to raise capital, but operating losses and higher G&A are widening the deficit and increasing reliance on external financing.

Key facts & metrics
- Cash and cash equivalents (June 30, 2025): $5,570,730.
- Cash reported as of August 6, 2025: ~ $5.0 million (management said sufficient for at least 12 months from filing).
- Total assets (June 30, 2025): $5,978,431; Total liabilities: $1,679,518; Stockholders' equity: $4,298,913.
- Accumulated deficit: $(33,235,450).
- Net loss: three months ended June 30, 2025 = $(3,667,287); six months = $(7,512,667).
- Cash used in operating activities (six months ended June 30, 2025): $(7,674,557).
- Net loss per share, basic and diluted: three months $(1.87); six months $(3.95).
- Weighted average shares (six months): 1,903,222; Outstanding shares (Aug 11, 2025): 2,046,854.
- Operating expense drivers (six months): G&A $4,910,970 (up ~110% YoY); R&D $2,745,379 (up 46% YoY).
- Equity-based compensation (six months): $1,141,409; unrecognized stock comp at June 30, 2025: $3.2M to be expensed over ~2.35 years.
- ATM and equity raises: H1 2025 sold 186,294 shares at $17.97 avg - gross ~$3,348,000, net ~$3,199,000; July 1-14, 2025 sold 39,741 shares - gross ~$516,000, net ~$499,000.

What's happening inside (operational & R&D focus)
- Clinical focus: moving tecarfarin into trials for ESKD patients (transitioning to dialysis) and continuing to pursue orphan/fast-track indications (ESKD+AFib; LVAD).
- Clinical record: tecarfarin has been studied in 11 trials in >1,000 people; EMBRACE-AC (607 patients) reported a blinded tecarfarin major bleeding rate of 1.6% and no thrombotic events - supportive data for targeted rare indications.
- Organizational changes: higher public-company costs, added personnel (COO hired earlier), severance and CMC buildout increased R&D and G&A.

Positive aspects of the income statement / business
- R&D investment is increasing and targeted toward late-stage, orphan/fast-track indications - a logical place to add value for a VKA alternative.
- Company has been able to access capital via ATM and warrant exercises (H1 2025 ATM proceeds ~$3.2M net; July ATM ~$499k net), extending runway near-term.
- Research-driven spending (CMC, clinical prep) is visible and tied to near-term clinical catalysts (trial initiation announced Aug 5, 2025).

Negative aspects of the income statement / risks
- Large and growing operating losses: six-month net loss $7.51M; operating cash burn ~$7.67M in six months - cash decline is material.
- Rapid increase in G&A (110% YoY for the six months) driven by public-company costs and rising stock-based comp, which increases fixed overhead and dilutive compensation expense.
- Dependence on equity financing and ATM sales to fund operations - dilutive and not guaranteed at favorable terms.
- Management warns additional funding will be required for any Phase 3 trial; inability to raise funds would force program delays or scope reductions.
- Accumulated deficit $(33.2M) and limited cash cushion create execution risk despite the "12-month" runway statement.

Near-term catalyst & outlook
- Catalyst: initiation and enrollment of the ESKD (transition to dialysis) study for tecarfarin (enrollment expected later in 2025). Successful data or clear enrollment progress would materially de-risk the story.
- Financing needs: the company expects current cash to cover ~12 months but will need additional capital to support Phase 3 or broader development - financing strategy includes partnering, equity, or debt (no guarantees).

Bottom line: Cadrenal (NASDAQ: CVKD) is progressing clinically with a focused strategy on rare anticoagulation indications and has short-term financing via ATM sales. However, rising G&A, persistent losses, and heavy cash burn mean the company remains dependent on further financing to advance tecarfarin beyond planned trials.